Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine
Polytherapy in Migraine
Headache disorders represent the most frequent clinical problem among neurological diseases . Migraine alone affects nearly 14% of the global population, and is the first cause of disability in people under 50 years of age, representing a real challenge for healthcare systems . Evidence of multiple comorbidities in the migraine population, especially at cardio-cerebrovascular, psychiatric, metabolic, and musculoskeletal levels, has led to an observed increase in clinical practice of patients undergoing multiple pharmacological therapies [3, 4, 5, 6]. The use of different drugs in the same migraine patient significantly increases the risk of potentially serious adverse events (AEs) . As a consequence, the development and implementation of precision medicine in clinical practice addresses this increased clinical risk, allowing advanced and early evaluation of possible drug–drug interactions (DDIs), and guiding clinical prescription and monitoring . We...
Compliance with Ethical Standards
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors declare that they have no conflict of interest.
All the described procedures are conducted in compliance with the latest version of the Declaration of Helsinki and according to clinical guidelines.
- 3.van Os HJA, Mulder IA, Broersen A, Algra A, van der Schaaf IC, Kappelle LJ, Velthuis BK, Terwindt GM, Schonewille WJ, Visser MC, Ferrari MD, van Walderveen MAA, Wermer MJH, DUST Investigators. Migraine and cerebrovascular atherosclerosis in patients with ischemic stroke. Stroke. 2017;48:1973–5.CrossRefPubMedGoogle Scholar
- 6.de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M, Barbaro MGF. Symptoms of central sensitization and comorbidity for juvenile fibromyalgia in childhood migraine: an observational study in a tertiary headache center. J Headache Pain. 2017;18:59.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Borro M, Simmaco M, Aceti A, Barni S, De Luca A, Fineschi V, Frati P, Girardi P, Miozzo M, Nati G, Nicoletti F, Santini D, Marchetti P. H2020 and beyond: skip discrepancy between theory and practice of personalized medicine. A position paper by the Italian Society of Personalized Medicine. Curr Pharm Biotechnol. 2016;17:926–9.CrossRefPubMedGoogle Scholar
- 20.Williamson EM. Interactions between herbal and conventional medicines: the role of cytochrome P450 enzymes and p-glycoprotein. Pharmacologyonline. 2006;2:200–5.Google Scholar